Description
GL-3 RT
Triple-Receptor Research Peptide
A next-generation synthetic peptide engineered as a unimolecular agonist of three metabolic receptors simultaneously — a new frontier in metabolic and obesity research.
| 15 mgVial | 20 mgVial | 30 mgVial | 40 mgVial |
A unimolecular tri-agonist — engineered to target three metabolic pathways at once.
| GL-3 RT is a synthetic peptide engineered as a single-molecule agonist of three distinct metabolic receptors simultaneously: GLP-1, GIP, and the glucagon receptor. By engaging all three pathways in a coordinated manner, the peptide produces effects that are not observed with single- or dual-receptor agonists, and it has rapidly become a central subject of contemporary metabolic and obesity research.
At Guardian Labs, we provide research-grade GL-3 RT rigorously tested to ensure purity exceeding ninety-nine percent — ensuring your laboratory data regarding metabolic homeostasis, energy expenditure, and body composition remains accurate and reproducible. |
By recruiting GLP-1, GIP, and glucagon signalling within a single molecule, GL-3 RT represents a step beyond previous incretin research — engaging satiety, insulin sensitivity, and energy expenditure in concert.
|
Three receptors, one molecule — how the tri-agonist orchestrates a metabolic response.
i
GLP-1 ReceptorActivation of the GLP-1 receptor enhances glucose-dependent insulin secretion, slows gastric emptying, and reduces appetite via central satiety pathways. |
ii
GIP ReceptorEngagement of the glucose-dependent insulinotropic polypeptide receptor improves insulin sensitivity and adipose tissue function in metabolic models. |
iii
Glucagon ReceptorGlucagon receptor agonism increases resting energy expenditure and stimulates hepatic lipid metabolism — the third arm of the tri-agonist effect. |
On Tri-Agonism
What distinguishes GL-3 RT from single-receptor (GLP-1) and dual-receptor (GLP-1/GIP) agonists is the addition of glucagon receptor activity. The glucagon arm contributes to increased energy expenditure — a thermogenic component absent from earlier-generation peptides — and is widely viewed as the mechanism underlying its observed efficacy in advanced metabolic research.
Primary subjects of investigation — strictly laboratory use.
A.01
Body CompositionStudies on the reduction of adipose tissue mass, visceral fat depots, and metabolic markers in diet-induced obesity models. |
A.02
Glycemic ControlInvestigations into glucose homeostasis, insulin sensitivity, and pancreatic beta-cell function in metabolic dysfunction models. |
A.03
Energy ExpenditureResearch into glucagon-mediated thermogenesis, basal metabolic rate, and whole-body energy balance. |
A.04
Hepatic FunctionStudies of hepatic lipid metabolism, fatty liver models, and the effect of multi-receptor agonism on liver tissue composition. |
Peer-reviewed literature supporting the research potential of this peptide.
| i. |
Tri-Agonism & Body CompositionA landmark phase 2 investigation reported that triple-receptor agonist administration produced substantial reductions in body mass index and adipose tissue volume in subjects with obesity — with effects exceeding those previously observed with single- and dual-receptor compounds. |
View on PubMed → |
| ii. |
Glycemic OutcomesInvestigators reported significant improvements in glycated hemoglobin and fasting glucose markers in metabolic dysfunction models, with concurrent enhancements in insulin sensitivity attributable to combined GLP-1 and GIP receptor engagement. |
View on PubMed → |
| iii. |
Energy Expenditure & ThermogenesisMechanistic research into the glucagon-receptor arm reported increased basal metabolic rate and enhanced thermogenic activity — supporting the hypothesis that the glucagon component is central to the molecule’s superior body-composition outcomes. |
View on PubMed → |
| iv. |
Hepatic Steatosis ReductionAn exploratory analysis examining hepatic outcomes reported significant reductions in liver fat fraction and improvements in liver enzyme markers — consistent with the proposed role of glucagon-receptor agonism in hepatic lipid metabolism. |
View on PubMed → |
Certificate of analysis available upon request.
| Class | Synthetic Tri-Agonist Peptide |
| Receptor Targets | GLP-1 / GIP / Glucagon |
| Format | Lyophilized Powder (Freeze-dried) |
| Vial Sizes | 15 mg / 20 mg / 30 mg / 40 mg |
| Purity | > 99% (HPLC Verified) |
| Storage | Store at −20°C |
| Reconstitution | Bacteriostatic Water |
Reviews
There are no reviews yet.